评估氯吡格雷联合前列地尔对急性脑梗死患者血液流变学指标、血小板聚集率的影响及临床疗效分析

Clinical analysis of clopidogrel combined with alprostadil on treatment of patients with acute cerebral infarction

目的研究氯吡格雷联合前列地尔对于急性脑梗死患者血液流变学、血小板聚集率的影响,并评估其临床疗效及安全性。方法 80例急性脑梗死患者随机均分为两组,对照组采用常规治疗方法;治疗组在常规治疗基础上采用氯吡格雷联合前列地尔治疗方法,观察两组患者血液流变学指标、血小板聚集率、临床疗效及安全性。结果对照组总有效率为77.5%,治疗组总有效率为95.0%。治疗组总有效率明显高于对照组,其间差异有统计学意义(P<0.05)。治疗组临床症状改善情况、血液流变学指标、血小板聚集率改善明显优于对照组(P<0.05)。治疗期间观察各组均无明显副作用。结论氯吡格雷联合前列地尔治疗急性脑梗死临床疗效明显,且安全性高,值得临床推广及应用。

Objective To investigate the effect of clopidogrel combined with alprostadil for the hemorheology and platelet aggravation in the patients with acute cerebral infarction, and to evaluate the clinical efficacy and safety. Methods 80cases of acute cerebral infarction were randomly divided into 2 groups, control group with conventional treatment methods, and the treatment group was treated by clopidogrel combined with alprestadil on the basis of conventional therapy, observed their hemorheology, platelet aggravation, clinical efficacy and safety. Results In the control group, the total effective rate was 77.5%, and the total effective rate of treatment group was 95%. The total effective rate of treatment group was significantly higher than the control group, there was statistically significant difference （ P 〈 0. 05 ）. The clinical symptom, hemorheology, and platelet aggravation improved significantly better than the control group （P 〈 0. 05）. During the treatment, there were no obvious side effects. Conclusions Clopidogrel combined with alprostadil in the treatment of acute cerebral infarction was significantly better than pure conventional treatment methods, and this is more safe, and is worthy of clinical application.